| dc.contributor.author | Weisel, Katja |  | 
| dc.date.accessioned | 2016-03-18T11:10:03Z |  | 
| dc.date.available | 2016-03-18T11:10:03Z |  | 
| dc.date.issued | 2015 |  | 
| dc.identifier.issn | 0887-6924 |  | 
| dc.identifier.uri | http://hdl.handle.net/10900/68881 |  | 
| dc.language.iso | en | de_DE | 
| dc.publisher | Nature Publishing Group | de_DE | 
| dc.relation.uri | http://dx.doi.org/10.1038/leu.2015.80 | de_DE | 
| dc.rights | info:eu-repo/semantics/closedAccess |  | 
| dc.subject.ddc | 610 | de_DE | 
| dc.title | Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma | de_DE | 
| dc.type | Article | de_DE | 
| utue.quellen.id | 20151209042647_01000 |  | 
| utue.publikation.seiten | 1721-1729 | de_DE | 
| utue.personen.roh | Mai, E. K. |  | 
| utue.personen.roh | Bertsch, U. |  | 
| utue.personen.roh | Duerig, J. |  | 
| utue.personen.roh | Kunz, C. |  | 
| utue.personen.roh | Haenel, M. |  | 
| utue.personen.roh | Blau, I. W. |  | 
| utue.personen.roh | Munder, M. |  | 
| utue.personen.roh | Jauch, A. |  | 
| utue.personen.roh | Schurich, B. |  | 
| utue.personen.roh | Hielscher, T. |  | 
| utue.personen.roh | Merz, M. |  | 
| utue.personen.roh | Huegle-Doerr, B. |  | 
| utue.personen.roh | Seckinger, A. |  | 
| utue.personen.roh | Hose, D. |  | 
| utue.personen.roh | Hillengass, J. |  | 
| utue.personen.roh | Raab, M. S. |  | 
| utue.personen.roh | Neben, K. |  | 
| utue.personen.roh | Lindemann, H-W |  | 
| utue.personen.roh | Zeis, M. |  | 
| utue.personen.roh | Gerecke, C. |  | 
| utue.personen.roh | Schmidt-Wolf, I. G. H. |  | 
| utue.personen.roh | Weisel, K. |  | 
| utue.personen.roh | Scheid, C. |  | 
| utue.personen.roh | Salwender, H. |  | 
| utue.personen.roh | Goldschmidt, H. |  | 
| dcterms.isPartOf.ZSTitelID | Leukemia | de_DE | 
| dcterms.isPartOf.ZS-Issue | 8 | de_DE | 
| dcterms.isPartOf.ZS-Volume | 29 | de_DE | 
| utue.fakultaet | 04 Medizinische Fakultät | de_DE |